5487-33-2

Basic information

• Product Name: Benzeneacetic.acid,4-methoxy-3-(phenylmethoxy)-
• Synonyms: Benzeneacetic.acid,4-methoxy-3-(phenylmethoxy)-;(3-Benzyloxy-4-methoxyphenyl)acetic acid;2-(3-(benzyloxy)-4-Methoxyphenyl)acetic acid;4-Methoxy-3-(phenylMethoxy)benzeneacetic Acid;NSC 131754
• CAS NO: 5487-33-2
• Molecular Formula: C₁₆H₁₆O₄
• Molecular Weight: 272.3
• Product Categories: Agonist
• Mol File: 5487-33-2.mol
• Article Data: 19

Chemical Properties

• Melting Point: 126-130 °C
• Boiling Point: 440.1°Cat760mmHg
• Flash Point: 162.6°C
• Appearance: /
• Density: 1.207g/cm³
• Vapor Pressure: 1.61E-08mmHg at 25°C
• Refractive Index: 1.581
• Solubility: Dichloromethane, Ethyl Acetate
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: Benzeneacetic.acid,4-methoxy-3-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic.acid,4-methoxy-3-(phenylmethoxy)-(5487-33-2)
• EPA Substance Registry System: Benzeneacetic.acid,4-methoxy-3-(phenylmethoxy)-(5487-33-2)

Safety Data

• Hazardous Substances Data: 5487-33-2(Hazardous Substances Data)

Usage

Chemical Properties

Beige Solid

Uses

3-(Benzyloxy)-4-Methoxyphenylacetic Acid can act as reagent used in the preparation of inhibitors and antiinflammatory agents.

InChI:InChI=1/C16H16O4/c1-19-14-8-7-13(10-16(17)18)9-15(14)20-11-12-5-3-2-4-6-12/h2-9H,10-11H2,1H3,(H,17,18)

Upstream product

• 71146-77-5 2-(3-(benzyloxy)-4-methoxyphenyl)acetamide 
• 1699-39-4 2-(3-(benzyloxy)-4-methoxyphenyl)acetonitrile 
• 5164-91-0 (3-benzyloxy-4-methoxy-phenyl)-pyruvic acid 
• 23428-78-6 4-[(3-benzyloxy-4-methoxy-phenyl)-thioacetyl]-morpholine 
• 144864-76-6 1-methylsulfinyl-1-methylthio-2-(3-benzyloxy-4-methoxyphenyl)ethylene 
• 156539-06-9 3-(Benzyloxy)-4-methoxyphenylacetic acid 2-iodoethyl ester 
• 143-33-9 sodium cyanide 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 63909-29-5 (E)-2-(benzyloxy)-1-methoxy-4-(2-nitrovinyl)benzene 
• 621-59-0 isovanillin 
• 100-44-7 benzyl chloride 
• 1860-60-2 3-benzyloxy-4-methoxy-benzyl alcohol 
• 100-39-0 benzyl bromide 
• 1699-38-3 3-benzyloxy-4-methoxy-benzyl chloride 

Downstream Products

• 1699-40-7 (3-benzyloxy-4-methoxy-phenyl)-acetic acid-(4-benzyloxy-3-methoxy-phenethylamide) 
• 54313-33-6 2-(3-(benzyloxy)-4-methoxyphenyl)acetyl chloride 
• 78792-73-1 5-benzyloxy-4-methoxy-2-nitrophenylacetic acid 
• 1131-94-8 homoisovanillic acid 
• 144864-77-7 (4R,5S)-3-<2-(3-benzyloxy-4-methoxyphenyl)-1-oxoethyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 93279-68-6 (E)-α-(3-(Benzyloxy)-4-methoxyphenyl)-3,4-dimethoxy-2-nitrocinnamic acid 
• 21610-80-0 3-benzyloxy-4-methoxyphenylacetic acid ethyl ester 
• 21411-26-7 N-[3-(benzyloxy)-4-methoxyphenethyl]-2-[3-(benzyloxy)-4-methoxyphenyl]acetamide 
• 113948-36-0 2-[2-(3-Benzyloxy-4-methoxy-phenyl)-acetylamino]-3-(4-hydroxy-3-methoxy-phenyl)-propionic acid methyl ester 
• 113948-36-0 2-[2-(3-Benzyloxy-4-methoxy-phenyl)-acetylamino]-3-(4-hydroxy-3-methoxy-phenyl)-propionic acid methyl ester 
• 73168-78-2 N-(3,4-methylenedioxyphenethyl)-3-benzyloxy-4-methoxyphenylacetic acid amide 
• 18028-10-9 N-(3-Benzyloxy-4-methoxy-phenyl)-N-(3,4-dimethoxy-phenaethyl)-acetamid 
• 156539-00-3 3-(Benzyloxy)-4-methoxyphenylacetic acid 2-bromoethyl ester 
• 23428-79-7 2-(3-Benzyloxy-4-methoxy-phenyl)-N-[2-(3-bromo-4,5-dimethoxy-phenyl)-ethyl]-acetamide 

Relevant articles and documents

Full-synthetic method of racemic tetrandrine

The invention discloses a full-synthetic method of racemic tetrandrine, and belongs to the technical field of drug synthesis. The full-synthetic method of the racemic tetrandrine comprises the steps that a synthetic route adopts a convergence synthesis method, a 5-bromovanillin, namely a compound 1 and 3-hydroxy-4-methoxyphenylacetic acid, namely a compound 5 are taken as starting materials to obtain a compound 4 and a compound 6 respectively, then the compound 4 and the compound 6 are taken as raw materials to synthesize a compound 11, a compound 19 is synthesized from the compound 11, and finally, the compound 11 reacts with the compound 19. The full-synthetic method of the racemic tetrandrine has the advantages that the synthetic efficiency is higher, the yield is higher, and the cost is lower; the reaction conditions are milder, the operation is simple and convenient, the industrial value is higher, and a reference is provided for the full-synthetic method of optical voidness tetrandrine.

Designing new analogs for streamlining the structure of cytotoxic lamellarin natural products

Despite the therapeutic potential of marine-derived lamellarin natural products, their preclinical development has been hampered by their lipophilic nature, causing very poor aqueous solubility. In order to develop more drug-like analogs, their structure was streamlined in this study from both the cytotoxic activity and lipophilicity standpoints. First, a modified total synthetic route was successfully devised to construct a library of 59 systematically designed lamellarin analogs, which were then subjected to cytotoxicity and log P determinations. Along with the 25 first-generation lamellarins previously synthesized in our laboratory, the structure-activity and structure-lipophilicity relationships were extensively evaluated. Our results clearly indicated the additional structural requirements around the lamellarin skeleton which, when combined with those reported previously, can provide invaluable guidance for further modifications to increase the aqueous solubility of these compounds.

Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [11C]A-740003 as a novel tracer of neuroinflammation

Neuroinflammation, in particular activation of microglia, is thought to play an important role in the progression of neurodegenerative diseases. In activated microglia, the purinergic P2X7 receptor is upregulated. A-740003, a highly affine and